Studies about gimeracil, a radiosensitizer
| Project/Area Number |
21591616
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | Sapporo Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
高木 克 札幌医科大学, 医学部, 研究員 (10404716)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2011: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2010: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2009: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | 放射線治療 / 放射線増感 / DNA2重鎖切断 / 相同組換え修復 / DNA 2重鎖切断 |
|---|
| Research Abstract |
We studied the radiosensitizing effects of gimeracil, a component of TS-1, an anti-cancer drug. We obtained the following results. Gimeracil had the radiosensitizing effects in all different 10 cells examined. Gimeracil did not influence the cell cycle. Gimeracil partially inhibited the homologous recombination repair(HR) of DNA double strand breaks. dihydropyrimidine dehydrogenase(DPYD) is the target protein for radiosensitization by Gimeracil. The inhibitors of DPYD such as Gimeracil could enhance the efficacy of radiotherapy through partial suppression of HR-mediated DNA repair.
|
Report
(4 results)
Research Products
(15 results)
-
-
-
[Journal Article] Gimeracil, an inhibitor of dihydropyrimidine dehydrogenase, inhibits the early step in homologous recombination2011
Author(s)
Sakata K, Someya M, Matsumoto Y, Tauchi H, Kai M, Toyota M, Takagi M, Hareyama M, Fukushima M
-
Journal Title
Cancer Sci
Volume: 102(9)
Pages: 1712-1716
NAID
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
